OYE Therapeutics


Meet our team


EXECUTIVE TEAM

image of Brett Dines RPh MBA

Brett Dines RPh MBA

CEO, Founder 

Mr. Dines was most recently the VP of Hospitals and Health Systems at Walgreens. In this role, he led the $9.2 Billion USD business development and strategic initiatives in 340B, transition of care, and integration of healthcare delivery systems for hospitals and health systems. Mr. Dines holds a B.A. in Pharmaceutical Sciences Purdue University, an MBA in Entrepreneurship and Operations Mgmt from DePaul University KellStadt Graduate School of Business, and serves as adjunct faculty at University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.

image of Robert J Spiegel, MD

Robert J Spiegel, MD 

Special Advisor to CEO

Interim Chief Medical Officer

Dr. Robert Spiegel, is special advisor to the CEO, is the former Chief Medical Officer Schering Corp where he served as SVP worldwide clinical development and participated in over 30 NDAs, notably during the development and commercial launch of Sugamadex. He is a Associate Professor at Weill Cornell Medical School and serves as an Advisor to Warburg Pincus. He is a member of the Board of several private and public biotech companies and serves as the President of Spiegel Consulting LLC. He is a graduate of Yale University (B.A.) and University of Pennsylvania (M.D.) and completed his medical training at the National Cancer Institute, NIH.

Image of Mike Hicks, COO


Michael Hicks, MBA

Chief Operating Officer

Past President and CEO at HSHS St Mary’s Hospital, Mr. Hicks also served as the Senior Vice President and Chief Operating Officer at UChicago Medicine - Ingalls Memorial. He is an experienced healthcare executive with a proven track record in ambulatory growth, hospital operations, physician practice acquisition and management, real estate management, laboratory services and clinical service line development. A long-standing Fellow of the American College of Healthcare Executives,  Mr. Hicks holds a BA in Communication from Purdue University and an MBA from Northwestern University - Kellogg School of Management.

Image of Eyal Barash, Ph.D. Esq

Eyal Barash, Ph.D. Esq

Corp Counsel/IP Strategy

Eyal is the principle at Barash Law. Previously he was chief patent counsel to SSCI, the world’s leader in solid-state chemistry and has extensive large practice experience. His focus is in patent procurement, including domestic and foreign patent preparation and lifecycle management strategies. Specific practice expertise includes uniquely qualified to evaluate complex innovator IP portfolios from a design around, generic perspective, including method-of-use claim coverage relative to the product label, Orange Book patent listing and data exclusivity, 505(b) 2 strategies, labeling carve-outs, and Patent Term Extensions. Northwestern Law, JD, UC Berkley MS Chemistry, and Indiana University chemistry degrees. Mr Barash most recently structured the exit of Endocyte to Merck.

Board of Directors

image of Brett Dines RPh MBA

Robert G. Funari 

Chairman 

Healthcare executive with broad CEO experience in both services and medical devices. 5+ exits to Fortune 500 companies, 2 exits greater than $1B each. Prior experience as Chairman of Board, Chair of Nominating and Corporate Governance Committee, and a member of Compensation Committees. Mr. Funari holds an MBA from Harvard University

image of Robert J Spiegel, MD

Brent D. Fassett, Esq

Board Observer and Outside Counsel

Mr Fassetts practice focus is emerging growth companies and investors in life sciences and health care companies. Counsel for Life Science transactional services. Cooley LLP is consistently rank #1 for global biotech & pharma licensing #1 for biotech and pharma venture financings for the last decade, including in 2018. Brent has also represented clients in a wide array of industries, including drug delivery, medical devices, communications, software and branded retail. BA University of Michigan. JD University of Michigan

Image of Mike Hicks, COO


Tushar Ramani, M.D.

Director

Dr. Tushar Ramani brings over 30 years of experience in the anesthesia industry to OYE Therapeutics, Most recently, Dr. Ramani worked with Summit Partners’ Healthcare & Life Sciences team as an Executive in Residence to identify growth investment opportunities in healthcare and evaluate prospects of existing investments. In connection with this appointment, he served as CEO of portfolio company, MedOptions, Inc., the nation's largest behavioral health services provider to post-acute care facilities. Dr. Ramani also recently served as CEO of CRH Medical Corporation (NYSE: CRHM), a supplier of anesthesia services and medical products for the gastroenterology practices, and has been a Director at several national healthcare service companies.

Formerly a practicing anesthesiologist and interventional pain management specialist, Dr. Ramani attended Jefferson Medical College in Philadelphia, interned at Morristown Memorial Hospital, and completed residency in Anesthesiology and Interventional Pain Management at Mount Sinai Medical School, New York.

SCIENTIFIC ADVISORY BOARD

Image of Jose Melendez, MD

Jose Melendez, MD 

Board Certified Anesthesiologist.  HCA Healthcare VP and Chief Medical Officer St. Mark's Hospital Salt Lake City, UT.  Former Chief Medical Officer University of Colorado Healthcare System. Expert in ambulatory surgery services and perioperative care. 

image of Peter Goldzweig, MD

Brian Davidson, MD 

Board Certified Anesthesiologist and reimbursement expert: American Society of Anesthesiologists, Executive MBA in Health Administration, Former CEO St Mary's Hospital.  

Image of Barry Rose, MD

Barry Rose, MD 

Board Certified Anesthesiologist UPMC and UCSF. Former research anesthesiologist and current clinical instructor UPMC and UCSF. Expert in anesthesia and perioperative care. 

Image of Dr Stephen Byrn, Ph.D.

Dr Stephen Byrn, Ph.D. 

Professor of Medicinal Chemistry in the Dept of Industrial and Physical Pharmacy, Purdue University. Dr Byrn is considered to have started the field of solid state chemistry of drugs in the USA. He has served as Chair Pharmaceutical Sciences Advisory Committee to the US FDA, chaired several USP committees, and is a consultant to numerous fortune 500 pharmaceutical and biotechnology firms. Dr Byrn leads OYE’s formulation development and intellectual property development. 

Recruiting two additional SABs